Key takeaways
Azathioprine (Imuran) and infliximab (Remicade) are both used to manage autoimmune conditions, but they have different mechanisms and uses. Azathioprine is an immunosuppressant available in both oral and IV forms, primarily used to prevent kidney transplant rejection and treat rheumatoid arthritis. In contrast, infliximab is a biologic DMARD given only through IV infusion by a healthcare provider, and it treats a broader range of autoimmune conditions, including Crohn's disease, ulcerative colitis, and severe plaque psoriasis. Azathioprine is available in a generic form, making it more affordable, while infliximab is only available as a brand name, which can be expensive. Both medications increase the risk of infections and certain cancers, but infliximab also has specific warnings for heart and liver problems. Additionally, azathioprine requires regular blood tests to monitor for side effects, whereas infliximab requires monitoring during and after infusions.
